Nasopharyngeal Cancer - Pipeline Review, H1 2020

February 2020 | 688 pages | ID: NBADF7A2413EN
Global Markets Direct

Abstracts

Nasopharyngeal Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2020, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 25, 18, 2, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 3, 8 and 1 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Nasopharyngeal Cancer - Overview
Nasopharyngeal Cancer - Therapeutics Development
Nasopharyngeal Cancer - Therapeutics Assessment
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development
Nasopharyngeal Cancer - Drug Profiles
Nasopharyngeal Cancer - Dormant Projects
Nasopharyngeal Cancer - Discontinued Products
Nasopharyngeal Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Nasopharyngeal Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Nasopharyngeal Cancer - Pipeline by Akeso Biopharma Inc, H1 2020
Nasopharyngeal Cancer - Pipeline by Alphamab Oncology, H1 2020
Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H1 2020
Nasopharyngeal Cancer - Pipeline by Apollomics Inc, H1 2020
Nasopharyngeal Cancer - Dormant Projects, H1 2020
Nasopharyngeal Cancer - Dormant Projects, H1 2020 (Contd..1), H1 2020
Nasopharyngeal Cancer - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nasopharyngeal Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Advenchen Laboratories LLC
Akeso Biopharma Inc
Alphamab Oncology
Ambrx Inc
Apollomics Inc
Argenx SE
Ascentage Pharma Group International
AstraZeneca Plc
Atara Biotherapeutics Inc
AVEO Oncology Inc
BeiGene Ltd
Biomics Biotechnologies Co Ltd
Bristol-Myers Squibb Co
Cell Medica Ltd
China Immunotech Co Ltd
Cullinan Oncology LLC
CytoMed Therapeutics Pte Ltd
Eli Lilly and Co
Eutilex Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Geneius Biotechnology Inc
Gmax Biopharm Ltd
Guangzhou Doublle Bioproduct Inc
Guangzhou Hanghua Bio Pharmaceutical Technology Co
Harbin Gloria Pharmaceuticals Co Ltd
Immunomic Therapeutics Inc
Incyte Corp
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Lion TCR Pte Ltd
Merck & Co Inc
Merck KGaA
Molecular Partners AG
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Otsuka Holdings Co Ltd
Oxford Vacmedix UK Ltd
PNP Therapeutics Inc
Polaris Pharmaceuticals Inc
RAPT Therapeutics Inc
Sapvax LLC
Shanghai GeneChem Co Ltd
Shanghai Junshi Bioscience Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Soricimed Biopharma Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Tessa Therapeutics Pte Ltd
TOT Biopharm Co Ltd
Vectorite Biomedical Inc
Viracta Therapeutics Inc
Xencor Inc
Xiangxue Life Sciences
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd